V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004907 | 10003072 | 1.8 | 71.3 | Adjuvant (A) | 2015-03-08 | 2015-03-08 | CARFILZOMIB | N | N | 10551428 | BEP |
| 10004908 | 10003073 | 1.65 | null | Neo-adjuvant (N) | 2017-03-20 | 2017-04-05 | CAPECITABINE + MITOMYCIN + RT | 2 | N | 10551663 | OCTREOTIDE |
| 10004909 | 10003073 | 1.76 | null | Palliative (P) | null | 2018-04-26 | HCX (Cape + Cisp + Tras) - Main | 2 | null | 10551663 | CAPECITABINE + CARBOPLATIN |
| 10004910 | 10003073 | 1.73 | 68.9 | Palliative (P) | 2016-10-04 | 2016-10-06 | BORTEZOMIB + THALIDOMIDE | 02 | N | 10551663 | CARBOPLATIN + RT |
| 10004911 | 10003074 | 1.67 | 73 | Curative (C) | 2017-01-30 | 2017-02-03 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10551778 | MITOMYCIN INTRAVESICULAR |
| 10004912 | 10003074 | null | 68.1 | Palliative (P) | 2014-10-06 | 2014-10-08 | BEP 5 Day | 02 | N | 10551778 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 10004913 | 10003075 | 1.62 | null | Palliative (P) | null | 2016-01-23 | TEMOZOLOMIDE | N | N | 10551912 | CARBO + FLUOROURACIL |
| 10004914 | 10003076 | 1.71 | 82.1 | Curative (C) | 2018-02-04 | 2018-02-13 | RCEOP | N | N | 10551942 | MITOMYCIN INTRAVESICULAR |
| 10004915 | 10003077 | 1.68 | null | Curative (C) | 2015-09-06 | 2015-08-30 | Trastuzumab 21 day loading dose | 02 | null | 10551979 | CMF |
| 10004916 | 10003077 | 0 | 81 | null | 2017-07-01 | 2017-07-02 | CARBOPLATIN + PACLITAXEL + RT | Y | null | 10551979 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004917 | 10003077 | 1.64 | 84.7 | Not known (9) | 2016-01-02 | 2016-01-23 | Cetuximab + FOLFIRI cycle1 | N | N | 10551979 | LENALIDOMIDE |
| 10004918 | 10003077 | null | 42.3 | Palliative (P) | 2016-05-05 | 2016-05-28 | Cetuximab 14 day | 02 | N | 10551979 | CETUXIMAB |
| 10004919 | 10003077 | null | 65.8 | Neo-adjuvant (N) | null | 2018-02-06 | ETOPOSIDE | 2 | N | 10551979 | CAPECITABINE + IRINOTECAN |
| 10004920 | 10003078 | 0 | 70 | Palliative (P) | 2016-01-07 | 2016-01-23 | STAR TRIAL | 1 | N | 10552473 | CHLVPP |
| 10004921 | 10003079 | null | 106 | Palliative (P) | 2014-11-16 | 2015-10-04 | CISPLATIN + FLUOROURACIL | N | N | 10552475 | CETUXIMAB + IRINOTECAN + MDG |
| 10004922 | 10003079 | 1.61 | 55 | Curative (C) | 2016-06-14 | 2016-06-14 | Cyclophosphamide Weekly PO | N | N | 10552475 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004923 | 10003080 | 1.93 | 74.3 | Adjuvant (A) | 2016-06-23 | 2016-06-29 | MPT | 02 | N | 10552907 | DACARBAZINE |
| 10004924 | 10003081 | 1.79 | 60 | Palliative (P) | 2018-02-01 | 2018-02-03 | Docetaxel + Nintedanib | N | N | 10552920 | SORAFENIB |
| 10004925 | 10003081 | 1.71 | 56.3 | Palliative (P) | 2017-11-05 | 2017-11-08 | BLEOMYCIN | 02 | N | 10552920 | LENALIDOMIDE |
| 10004926 | 10003081 | 1.64 | 68 | Palliative (P) | 2017-06-12 | 2017-06-22 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | null | 10552920 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10004927 | 10003082 | 1.75 | 69.2 | Palliative (P) | null | 2015-10-09 | Capecitabine + Mitomycin | 02 | N | 10552953 | PAZOPANIB |
| 10004928 | 10003083 | 1.69 | 93 | Palliative (P) | 2015-05-29 | 2015-06-09 | Cetuximab +Cisplatin + FU (Cycle 1) | 2 | N | 10553132 | CLADRIBINE |
| 10004929 | 10006753 | 1.74 | 87.6 | Palliative (P) | 2016-05-05 | 2016-05-07 | Doxorubicin 75mg/m2 | N | N | 10553538 | NOT MATCHED |
| 10004930 | 10003084 | 1.69 | 79.6 | null | 2013-10-01 | 2013-10-01 | Folfirinox | 02 | N | 10553578 | VINORELBINE |
| 10004931 | 10003084 | 0 | 0 | Not known (9) | 2015-06-01 | 2015-06-02 | Sunitinib | N | N | 10553578 | AFATINIB |
| 10004932 | 10003084 | 1.86 | 85 | Disease modification (D) | 2016-02-26 | 2016-02-29 | BENDAMUSTINE + OFATUMUMAB | null | N | 10553578 | CAPECITABINE + IRINOTECAN |
| 10004933 | 10003084 | 1.66 | 66.2 | Curative (C) | 2015-01-05 | 2015-01-07 | Erlotinib | N | N | 10553578 | CARFILZOMIB + CYCLOPHOSPHAMIDE |
| 10004934 | 10003085 | 1.65 | 0 | Disease modification (D) | 2015-09-05 | 2015-09-05 | Mitomycin Intravesical | N | N | 10553837 | ALEMTUZUMAB |
| 10004935 | 10003086 | 1.61 | 63.3 | Curative (C) | 2017-03-10 | 2017-04-01 | Cyclophosphamide + Docetaxel | N | N | 10553903 | AC |
| 10004936 | 10003087 | 1.86 | null | Adjuvant (A) | 2017-05-04 | 2017-05-22 | Chlorambucil + Pred + Rituximab | 02 | N | 10553913 | MYELOMA XI TRIAL |
| 10004937 | 10006755 | 1.76 | null | Curative (C) | 2015-12-27 | 2015-12-27 | RCEOP | N | null | 10554041 | BORTEZOMIB + THALIDOMIDE |
| 10004938 | 10006755 | 1.73 | 67 | Neo-adjuvant (N) | 2016-07-29 | 2016-07-30 | Bendamustine +/- Prednisolone | N | N | 10554041 | CISPLATIN + FLUOROURACIL |
| 10004939 | 10006756 | null | 70 | Palliative (P) | 2015-10-30 | 2015-11-05 | Mitomycin Intravesical | N | null | 10554370 | MPV |
| 10004940 | 10003088 | 1.79 | 72 | Palliative (P) | 2019-02-08 | 2019-02-15 | CYCLOPHOSPHAMIDE + RITUXIMAB + Dexamethasone | 02 | N | 10554386 | CHOEP |
| 10004941 | 10003089 | 1.78 | 53.8 | Curative (C) | 2014-04-04 | 2014-04-04 | OFATUMUMAB | N | N | 10554411 | CETUXIMAB + IRINOTECAN + MDG |
| 10004942 | 10003090 | 1.79 | 98.4 | Neo-adjuvant (N) | 2017-06-09 | 2017-06-09 | MPT | N | N | 10554456 | ATEZOLIZUMAB |
| 10004943 | 10003091 | 1.67 | 75 | Palliative (P) | 2015-11-14 | 2015-11-15 | FLUOROURACIL + MITOMYCIN | N | N | 10554499 | IPILIMUMAB + NIVOLUMAB |
| 10004944 | 10003092 | 1.66 | null | Neo-adjuvant (N) | 2017-09-04 | 2017-09-06 | AFATINIB | N | N | 10554549 | CYTARABINE |
| 10004945 | 10003093 | 1.79 | 75.45 | Neo-adjuvant (N) | 2015-03-22 | 2015-04-15 | Pazopanib | 02 | N | 10554676 | IDELALISIB |
| 10004946 | 10003094 | 1.6 | 67 | Curative (C) | 2018-05-18 | 2018-05-19 | STAR TRIAL | Y | N | 10554783 | FLAIR TRIAL |
| 10004947 | 10003095 | 1.72 | 71.8 | Disease modification (D) | 2015-04-15 | 2015-05-12 | Cetuximab + Oxaliplatin + MdG Load | N | N | 10554850 | OFATUMUMAB |
| 10004948 | 10003096 | 1.82 | 73.8 | null | 2018-01-16 | 2018-01-26 | RCEOP | 02 | N | 10554902 | GEMCITABINE + NAB-PACLITAXEL |
| 10004949 | 10003097 | 0 | 67.2 | Curative (C) | 2017-05-20 | 2017-05-28 | Cladribine (subcut) 5 days | N | N | 10554998 | FLUOROURACIL + MITOMYCIN |
| 10004950 | 10003097 | 1.68 | 51 | null | 2016-11-11 | 2016-11-11 | Bevacizumab + Cape + Oxali 14day | N | N | 10554998 | DOXORUBICIN EMBOLISATION |
| 10004951 | 10003098 | null | 63.3 | Palliative (P) | 2018-07-26 | 2018-08-09 | Vemurafenib | 1 | N | 10555122 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10004952 | 10006758 | null | 100 | Adjuvant (A) | 2017-07-31 | 2017-07-31 | CETUXIMAB + RT | N | N | 10555227 | RUXOLITINIB |
| 10004953 | 10003099 | 1.74 | 56.5 | Palliative (P) | 2016-05-04 | 2016-05-15 | MITOMYCIN | 01 | N | 10555236 | EVEROLIMUS |
| 10004954 | 10003100 | 1.7 | 73 | Adjuvant (A) | 2016-04-29 | 2016-05-13 | RIALTO TRIAL | 02 | Y | 10555366 | CETUXIMAB |
| 10004955 | 10006759 | 1.67 | 92.4 | Neo-adjuvant (N) | 2017-06-19 | 2017-07-15 | Cyclophosphamide + Dex + Rituximab | 01 | Y | 10555469 | BENDAMUSTINE |
| 10004956 | 10003101 | 1.63 | 74.2 | Adjuvant (A) | 2018-01-25 | 2018-02-28 | MYELOMA XI TRIAL | N | null | 10555729 | TRASTUZUMAB |